Product Information
DICLOXACILLIN 250 MG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.5904 per EA under NDC 00093312301. Its NADAC has been published 636 times since Nov 28, 2013.
FDA first approved this application on Jun 3, 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093312301
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DICLOXACILLIN SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA062286FDA Approved
6/3/1982
TE Code
AB
On Market Since
9/30/1990
Pharmacological Classes
Price Statistics
The NADAC for DICLOXACILLIN 250 MG CAPSULE has been published 636 times since Nov 28, 2013, and over the history we have for it it has risen 172.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5904 per EA |
|---|---|
| All-time high | $0.6096 (Oct 16, 2019) |
| All-time low | $0.2167 (Nov 28, 2013) |
| 52-week high | $0.6071 |
| 52-week low | $0.5421 |
| Median price | $0.4706 |
| Average price | $0.4376 |
| Largest weekly change | +59.7% (Jul 20, 2016) |
| Weeks tracked | 636 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dicloxacillin Sodium market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dicloxacillin Sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Penicillin-class Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DICLOXACILLIN 250 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for DICLOXACILLIN 250 MG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $0.5904 per EA (NDC 00093312301), effective Sep 30, 2026.
How has the price of DICLOXACILLIN 250 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for DICLOXACILLIN 250 MG CAPSULE has risen 172.4%. It has been tracked across 636 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DICLOXACILLIN 250 MG CAPSULE?
Since Nov 28, 2013, the NADAC for DICLOXACILLIN 250 MG CAPSULE has ranged from a low of $0.2167 (Nov 28, 2013) to a high of $0.6096 (Oct 16, 2019), with a median of $0.4706 per EA.
Are there cheaper alternatives to DICLOXACILLIN 250 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of DICLOXACILLIN 250 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DICLOXACILLIN 250 MG CAPSULE?
DICLOXACILLIN 250 MG CAPSULE (NDC 00093312301) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.